ZonMw: The Netherlands Organisation for Health Research and Development
Phase 3
2009-10-01
A former study (submitted) in 32 severely asphyxiated infants participating in a randomized
double blind study, in which early postnatal allopurinol or a placebo (within 4 hours after
birth) was administered to reduce free radical formation and consequently
reperfusion/reoxygenation injury to the newborn brain, showed an unaltered high mortality and
no clinically relevant improvement in morbidity in infants treated with allopurinol. It was
hypothesized that postnatal allopurinol treatment started too late to reduce
reperfusion-induced free radical surge and that initiating allopurinol treatment of the fetus
with (imminent) hypoxia already via the mother during labor will be more effective to reduce
free radical-induced post-asphyxial brain damage.
A former study (submitted) in 32 severely asphyxiated infants participating in a randomized
double blind study, in which early postnatal allopurinol or a placebo (within 4 hours after
birth) was administered to reduce free radical formation and consequently
reperfusion/reoxygenation injury to the newborn brain, showed an unaltered high mortality and
no clinically relevant improvement in morbidity in infants treated with allopurinol. It was
hypothesized that postnatal allopurinol treatment started too late to reduce
reperfusion-induced free radical surge and that initiating allopurinol treatment of the fetus
with (imminent) hypoxia already via the mother during labor will be more effective to reduce
free radical-induced post-asphyxial brain damage.
This study will test the hypothesis that the administration of a xanthine oxidase inhibitor
(allopurinol) will prevent thiazide-induced hyperuricemia, which will result in better blood
pressure (BP) control in African Americans.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
